Table Graph
   

ivermectin - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.40 [0.13, 1.23]< 10%3 studies (3/-)94.4 %some concernnot evaluable moderatecrucial-
deaths 0.67 [0.45, 1.01]< 10%11 studies (10/1)97.3 %moderatecritical moderatecrucial-
deaths (time to event analysis only) 0.94 [0.51, 1.73]< 10%1 study (1/-)57.9 %NAnot evaluable crucial-
clinical deterioration 0.66 [0.32, 1.34]< 169%4 studies (4/-)87.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.56 [1.00, 2.43]> 10%5 studies (3/2)97.5 %moderateserious moderateimportant-
clinical improvement (7-day) 1.19 [0.69, 2.08]> 174%4 studies (3/1)73.5 %moderatenot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %NAnot evaluable important-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %NAnot evaluable important-
hospital discharge 1.25 [0.80, 1.95]> 10%3 studies (3/-)83.7 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.45 [0.22, 0.95]< 10%6 studies (6/-)98.2 %some concernnot evaluable moderateimportant-
viral clearance 1.21 [0.47, 3.12]> 173%4 studies (3/1)65.5 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 14 3.54 [1.03, 12.13]> 10%2 studies (2/-)97.8 %highnot evaluable lowimportant-
viral clearance by day 7 1.44 [0.69, 3.00]> 183%4 studies (4/-)83.7 %some concernnot evaluable moderateimportant-
ICU admission 1.10 [0.64, 1.86]< 10%3 studies (3/-)36.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.49 [0.20, 10.91]< 10%3 studies (3/-)34.8 %some concernnot evaluable moderateimportant-
adverse events 1.63 [0.89, 3.01]< 10%5 studies (5/-)5.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons